Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 6/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | GPR183 | P32249 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720788 | 0.90 | SRD5A2 (0.48) | SRD5A2SRD5A1MCHR1GPR183HPGD | |
| SCHEMBL23887638 | 0.84 | SRD5A2 (0.43) | SRD5A2SRD5A1 | |
| SCHEMBL23906274 | 0.79 | ESR2 (0.47) | NPC1RAB9A | |
| SCHEMBL20305039 | 0.79 | ALDH1A1 (0.46) | SRD5A2GPR183NPC1RAB9AHPGD | |
| SCHEMBL6082644 | 0.76 | ALDH1A1 (0.46) | SRD5A2NPC1RAB9A | |
| SCHEMBL6082641 | 0.76 | ALDH1A1 (0.46) | SRD5A2NPC1RAB9A | |
| SCHEMBL25268554 | 0.76 | SRD5A2 (0.44) | SRD5A2SRD5A1 | |
| SCHEMBL17750085 | 0.74 | LSS (0.51) | SRD5A2SRD5A1NPC1RAB9A | |
| SCHEMBL19994676 | 0.74 | SRD5A2 (0.48) | SRD5A2SRD5A1NPC1RAB9A | |
| SCHEMBL14720706 | 0.74 | SRD5A1 (0.51) | SRD5A2SRD5A1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4126824-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | Theravance Biopharma R&D IP, LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021203131-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | SRD5A2 1826/4885SRD5A1 1492/4885MCHR1 3557/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | SRD5A2 1826/4885SRD5A1 1492/4885MCHR1 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.